Oppenheimer (OPY) customer relationships: underwriting and advisory footprint investors should price
Thesis: Oppenheimer Holdings (OPY) operates as a middle‑market investment bank and full‑service broker‑dealer that monetizes through underwriting and advisory fees, commissions and AUM fees from wealth management, trading profits from market‑making and margin lending. Its business model is fee and transaction driven, with recurring wealth management revenue balanced by episodic capital‑markets mandates and underwriting assignments. For a concise view of relationship exposures, visit https://nullexposure.com/.
Why the relationship map matters to returns and risk
Oppenheimer’s client engagements—underwriting, placement, financial advisory and capital‑markets distribution—drive short‑term fee spikes and long‑term recurring revenue through wealth management. Key operating signals are concentration and counterparty mix: the firm serves a spectrum from individuals and middle‑market corporates to large institutional issuers across NA, EMEA and APAC. Disclosures also indicate material customer concentration in margin loans, which creates credit and liquidity sensitivity during market stress.
- Contracting posture: mix of transaction underwritings and ongoing custodial/wealth subscription fees supports diversified revenue streams (company disclosures).
- Concentration & criticality: two largest customer margin accounts represented ~52% of margin loans as of Dec 31, 2024, a critical company‑level exposure in the receivables book.
- Geographic footprint & clients: dominant U.S. Wealth Management network plus offices in London, Hong Kong, Israel and Switzerland supporting cross‑border advisory and placement.
- Roles: Oppenheimer performs as seller (underwriter/bookrunner), buyer/market‑maker, and service provider (wealth custodian/advisor) across engagements.
Relationship inventory: every reported customer engagement (news and filings)
Below are the items in the results set with a one‑line plain‑English summary and source citation (fiscal period as reported).
- GAIN (Gladstone Investment Corporation) — Oppenheimer acted as a joint book‑running manager for Gladstone’s 7.125% notes offering. Source: News‑Press press release (FY2026) — https://www.news-press.com/press-release/story/36474/gladstone-investment-corporation-prices-public-offering-of-7-125-notes-due-2031/ (FY2026).
- EVAX (Evaxion Biotech) — Oppenheimer served as sole book‑running manager for Evaxion’s initial public offering. Source: GlobeNewswire press release (FY2021) — https://www.globenewswire.com/news-release/2021/02/04/2170352/0/en/Evaxion-Biotech-Announces-Pricing-of-Initial-Public-Offering.html (FY2021).
- IMRX (Immuneering) — Leerink and Oppenheimer acted as joint bookrunners and placement agents on Immuneering’s offering and concurrent private placement. Source: ManilaTimes/GlobeNewswire summary (FY2025) — https://www.manilatimes.net/2025/09/25/tmt-newswire/globenewswire/immuneering-announces-proposed-underwritten-public-offering-of-class-a-common-stock-and-pre-funded-warrants-and-proposed-concurrent-private-placement-of-class-a-common-stock-and-class-b-common-stock-to-sanofi/2190017 (FY2025).
- IBIO (iBio) — LifeSci Capital and Oppenheimer acted as co‑placement agents on a $26M private placement. Source: GlobeNewswire (FY2026) — https://www.globenewswire.com/de/news-release/2026/01/09/3216001/0/en/iBio-Announces-26-Million-Private-Placement.html (FY2026).
- MLCIL (Mount Logan Capital / 180 Degree Capital) — Oppenheimer served as financial advisor to Mount Logan for a strategic business combination. Source: GlobeNewswire (FY2025) — https://www.globenewswire.com/news-release/2025/09/12/3149409/10573/en/Mount-Logan-Capital-Inc-and-180-Degree-Capital-Corp-Close-Strategic-Business-Combination.html (FY2025).
- HNNAZ — Oppenheimer mentioned alongside Janney Montgomery Scott in a filing or announcement; involvement indicates distribution/underwriting activity. Source: ADVFN/EDGAR summary (FY2026) — https://br.advfn.com/noticias/EDGAR/2021/artigo/86126516 (FY2026).
- BRNS (Barinthus Biotherapeutics) — Oppenheimer was exclusive financial advisor to Barinthus Bio on a combination transaction. Source: GlobeNewswire (FY2025) — https://www.globenewswire.com/news-release/2025/09/30/3158744/0/en/Barinthus-Biotherapeutics-to-Combine-with-Clywedog-Therapeutics-to-Target-Metabolic-and-Autoimmune-Diseases.html (FY2025).
- ATAI (atai Life Sciences) — Oppenheimer acted as co‑manager on atai’s public offering. Source: Investing/GlobeNewswire (FY2025) — https://www.investing.com/news/company-news/atai-life-sciences-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-common-shares/ and https://www.globenewswire.com/news-release/2025/10/16/3168331/0/en/atai-Life-Sciences-Announces-Proposed-Public-Offering-of-Common-Shares.html (FY2025).
- GLAD (Gladstone Capital Corporation) — Oppenheimer acted as sole book‑running manager on a proposed offering. Source: Yahoo Finance (FY2025) — https://finance.yahoo.com/news/gladstone-capital-corporation-announces-proposed-200500711.html (FY2025).
- OKUR (OnKure) — Oppenheimer served as capital markets advisor to OnKure in its merger/closing. Source: Yahoo Finance (FY2024) — https://finance.yahoo.com/news/onkure-announces-closing-merger-reneo-205700248.html (FY2024).
- GRDN (Guardian Pharmacy Services) — Stephens and Oppenheimer acted as co‑managers for a proposed offering. Source: FinancialContent/BizWire (FY2026) — https://markets.financialcontent.com/stocks/article/bizwire-2026-3-18-guardian-pharmacy-services-announces-launch-of-underwritten-public-offering-of-class-a-common-stock?Language=spanish (FY2026).
- HLXC (Helix Acquisition Corp III) — Leerink and Oppenheimer served as joint bookrunners for the SPAC offering. Source: FinancialContent (FY2026) — https://markets.financialcontent.com/stocks/article/gnwcq-2026-1-27-helix-acquisition-corp-iii-announces-closing-of-1725-million-initial-public-offering-including-the-full-exercise-of-the-underwriters-option-to-purchase-additional-shares (FY2026).
- CNCK (Coincheck Group) — Oppenheimer acted as financial advisor to Coincheck Group in a strategic acquisition. Source: Investing/MarketScreener (FY2026) — https://ng.investing.com/news/company-news/coincheck-group-completes-acquisition-of-3iq-digital-asset-manager-93CH-2368260 and https://www.marketscreener.com/news/coincheck-group-n-v-completed-the-acquisition-of-97-stake-in-3iq-digital-holdings-inc-from-monex-ce7e5cdddf8ff327 (FY2026).
- RWAYL (Runway Growth Finance) — Oppenheimer was one of the joint book‑running managers on an unsecured notes offering. Source: Investing/Markets (FY2026) — https://uk.investing.com/news/company-news/runway-growth-finance-launches-unsecured-notes-offering-93CH-4470949 and https://www.investing.com/news/company-news/runway-growth-finance-launches-unsecured-notes-offering-93CH-4466357 (FY2026).
- GSRM (GSR II / Bitcoin Depot combination) — Oppenheimer served as financial advisor to GSRM on a business combination. Source: FintechFutures and GlobeNewswire (FY2022) — https://www.fintechfutures.com/press-releases/bitcoin-depot-a-leading-bitcoin-atm-operator-to-become-a-publicly-traded-company-via-business-combination-with-gsr-ii-meteora-acquisition-corp- and https://www.globenewswire.com/news-release/2022/08/25/2504442/0/en/Bitcoin-Depot-a-Leading-Bitcoin-ATM-Operator-to-Become-a-Publicly-Traded-Company-Via-Business-Combination-With-GSR-II-Meteora-Acquisition-Corp.html (FY2022).
- IKT (Inhibikase Therapeutics) — LifeSci Capital and Oppenheimer acted as co‑lead managers on a proposed and priced $100M public offering. Source: GlobeNewswire (FY2025) — https://www.globenewswire.com/news-release/2025/11/20/3192391/0/en/Inhibikase-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html and https://www.globenewswire.com/news-release/2025/11/21/3192499/0/en/Inhibikase-Therapeutics-Announces-Pricing-of-100-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html (FY2025).
- APRE (Aprea Therapeutics) — Oppenheimer acted as lead placement agent on an oversubscribed $30M private placement and arranged investor meetings. Source: GlobeNewswire/MarketScreener/Globe & Mail/Bitget (FY2026) — https://www.globenewswire.com/news-release/2026/03/30/3264590/0/en/aprea-therapeutics-announces-oversubscribed-30-million-private-placement.html and https://www.marketscreener.com/news/aprea-therapeutics-inc-announced-that-it-expects-to-receive-30-0204-million-in-funding-from-soleu-ce7e51d9df8bf021 and https://www.theglobeandmail.com/investing/markets/stocks/APRE/pressreleases/1089415/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement/ and https://www.bitget.com/news/detail/12560605203720 (FY2026).
- TRVI (Trevi Therapeutics) — Oppenheimer acted as lead manager alongside major banks on Trevi’s proposed public offering. Source: GlobeNewswire (FY2026) — https://www.globenewswire.com/news-release/2026/04/16/3275817/0/en/Trevi-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html (FY2026).
- SGMT (Sagimet Biosciences) — Oppenheimer was among the joint bookrunning managers on an underwritten offering. Source: QuiverQuant (FY2026) — https://www.quiverquant.com/news/Sagimet+Biosciences+Inc.+Prices+Underwritten+Offering+of+29.2+Million+Shares+at+%246.00+Each%2C+Expected+to+Raise+%24175+Million (FY2026).
- ANTX (An2 Therapeutics) — Oppenheimer acted as lead manager for an underwritten offering. Source: StockTitan (FY2023) — https://www.stocktitan.net/news/ANTX/an2-therapeutics-announces-pricing-of-70-0-million-underwritten-m38icucc1plc.html (FY2023).
- AZ (A2Z Smart Technologies / A2Z cust2mate) — Oppenheimer served as broker for a $20M share buyback executed under SEC rules. Source: Globe & Mail / Investing (FY2026) — https://www.theglobeandmail.com/investing/markets/stocks/AZ-Q/pressreleases/1022574/a2z-cust2mate-extends-20-million-share-buyback-program-to-july-2026/ and https://www.investing.com/news/analyst-ratings/benchmark-reiterates-buy-on-a2z-smart-technology-stock-at-30-93CH-4522152 (FY2026).
- LITS (MEI Pharma / LITs reference) — Oppenheimer engaged to evaluate strategic alternatives for MEI Pharma in 2024. Source: GuruFocus (FY2026) — https://www.gurufocus.com/stock/LITS/summary?mobile= (FY2026).
- ALTI (Alti Global) — Oppenheimer served as dealer manager and solicitation agent on a warrants call offer. Source: SpacInsider (FY2023) — https://www.spacinsider.com/news/nick-clayton/alti-global-alti-calls-all-outstanding-warrants (FY2023).
- TH (Target Hospitality) — Oppenheimer acted as a co‑manager on secondary offerings and closings as part of a syndicate. Source: Yahoo Finance / Investing (FY2026) — https://finance.yahoo.com/markets/stocks/articles/target-hospitality-announces-closing-secondary-210000393.html and https://ca.investing.com/news/company-news/target-hospitality-completes-805m-share-secondary-offering-93CH-4584393 (FY2026).
- ALMS (Alumis) — Baird and Oppenheimer acted as co‑lead managers for an upsized public offering. Source: Yahoo Finance / QuiverQuant (FY2026) — https://finance.yahoo.com/news/alumis-announces-closing-upsized-public-210500721.html and https://www.quiverquant.com/news/Alumis+Inc.+Announces+Pricing+of+Upsized+Public+Offering+of+17.65+Million+Shares+at+%2417.00+Each (FY2026).
- PPHC (Public Policy Holding Company) — Oppenheimer and Canaccord named representatives of the underwriters in an underwriting agreement. Source: TradingView (FY2026) — https://www.tradingview.com/news/tradingview:cc2470af362bd:0-public-policy-holding-company-signs-underwriting-agreement-with-oppenheimer-and-canaccord/ (FY2026).
- MODD (Modular Medical) — Oppenheimer served as sole bookrunner on Modular Medical’s Nasdaq offering. Source: Renaissance Capital (FY2022) — https://www.renaissancecapital.com/IPO-Center/News/90166/Insulin-pump-developer-Modular-Medical-sets-terms-for-$30-million-Nasdaq-up (FY2022).
- RUBI (Rubicon Project/Rubi) — Oppenheimer acted as co‑manager on Rubicon’s IPO historical listing. Source: ExchangeWire (FY2014) — https://www.exchangewire.com/blog/2014/04/02/rubicon-project-ipos-today-nyse-rubi-as-another-ad-tech-player-goes-public/ (FY2014).
- AQB (AquaBounty Technologies) — Oppenheimer was one of the underwriters on AquaBounty’s public offering. Source: Faegre Drinker advisory note (FY2020) — https://www.faegredrinker.com/en/services/experience/2020/11/investment-banks-underwrite-aquabounty-technologies-inc-public-offering (FY2020).
- INO (Inovio) — Inovio suspended an ATM prospectus while the Sales Agreement with Oppenheimer remains in force pending a new prospectus. Source: TradingView (FY2026) — https://www.tradingview.com/news/tradingview:349c769e9e125:0-inovio-suspends-atm-prospectus-after-3-2m-sold-under-program/ (FY2026).
- LYTS (LSI Industries) — Oppenheimer joined other underwriters on a large equity issuance and exercised the overallotment option. Source: Globe & Mail (FY2026) — https://www.theglobeandmail.com/investing/markets/stocks/LYTS/pressreleases/546298/lsi-industries-prices-equity-offering-to-fund-growth/ (FY2026).
- FDUS (Fidus Investment Corporation) — Keefe Bruyette, Oppenheimer and ING acted as passive book‑runners on a notes offering. Source: GlobeNewswire (FY2025) — https://www.globenewswire.com/news-release/2025/03/12/3041780/15900/en/Fidus-Investment-Corporation-Prices-Public-Offering-of-100-Million-of-6-750-Notes-Due-2030.html (FY2025).
- CALC (CalciMedica / Graybug Vision combination) — Oppenheimer served as financial advisor on the merger and private placement. Source: GlobeNewswire (FY2023) — https://www.globenewswire.com/news-release/2023/03/20/2630834/0/en/CalciMedica-Announces-Closing-of-Merger-with-Graybug-Vision-and-Concurrent-Private-Placement.html (FY2023).
- AVBP (Arrivent Biopharma) — LifeSci Capital and Oppenheimer acted as lead managers on a $75M offering. Source: Mintz advisory note (FY2025) — https://www.mintz.com/insights-center/news-press/mintz-advises-arrivent-biopharma-75-million-underwritten-public-offering (FY2025).
- WT (WisdomTree) — Oppenheimer added as lead underwriter on a planned $525M fixed‑income offering. Source: SimplyWall.St community update (FY2026) — https://simplywall.st/community/narratives/us/diversified-financials/nyse-wt/wisdomtree/c3dk3ev9-wt-share-buyback-and-digital-asset-expansion-will-drive-further-upside/updates/17-analysts-have-trimmed-their-price-target-on-wisdomtree-to-dollar1 (FY2026).
- OCGN (Ocugen) — Oppenheimer acted as sole book‑running manager on a registered direct offering raising ~$22.5M. Source: TradingView / Globe & Mail / SahmCapital (FY2026) — https://www.tradingview.com/news/tradingview:4d12112846353:0-ocugen-inc-closes-22-5-million-stock-offering/ and https://www.theglobeandmail.com/investing/markets/stocks/OCGN-Q/pressreleases/37184866/ocugen-announces-22-5-million-public-stock-offering/ and https://www.sahmcapital.com/news/content/ocugen-inc-announces-closing-of-225-million-underwritten-registered-direct-offering-of-common-stock-2026-01-23 (FY2026).
(Each record above corresponds to a results entry; duplicate mentions in the results reflect multiple press placements or repeat coverage of the same engagement.)
What investors should take away
- Diverse fee channels: Oppenheimer’s revenue mix combines recurring wealth management fees with episodic capital‑markets fees from underwriting, placements and advisory — this lowers single‑deal dependency but raises sensitivity to underwriting cycles.
- Concentration risk: Company disclosures show two margin accounts representing ~52% of margin loans, a credit concentration that is material and operationally critical to receivables and liquidity metrics (company filings, Dec 31, 2024).
- Counterparty breadth: the roster spans private and public issuers, SPACs, biotechs and specialty finance, reflecting a middle‑market focus with selective large enterprise mandates across NA, EMEA and APAC.
- Operational posture: Oppenheimer functions both as principal market‑maker (inventory risk) and as agent underwriter—this hybrid model increases P&L volatility in stressed markets but also creates multiple fee and trading income levers.
Bottom line for allocators and operators
Oppenheimer’s customer relationships documented in public notices show a steady pipeline of underwriting and advisory work across sectors and geographies coupled with a large domestic wealth base. Investors should value OPY for recurring wealth fees and capital‑markets upside, while pricing in concentrated margin loan exposure and cyclical underwriting revenue. For a structured view of these relationships and additional signal sets, see https://nullexposure.com/.